Avanir Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Avanir Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3335
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Avanir Pharmaceuticals Inc (Avanir) a subsidiary of Otsuka America, Inc. is a biopharmaceutical company which focuses on developing medicines for patients suffering from central nervous system disorders. The company’s lead products include NUEDEXTA (AVP-923), a first-in-class dual N-methyl-D-aspartate (NMDA) rector antagonist and sigma-1 agonist is approved in the US and Europe for the treatment of pseudobulbar affect (PBA); and ONZETRA Xsail is for the treatment of migraine with or without aura in adult is approved in the US. Its AVP-786 has been developed for the treatment of depression and schizophrenia. The company is also developing various products under pipeline for the treatment of CNS disorders. Avanir is headquartered in Aliso Viejo, California, the US.

Avanir Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 10
Licensing Agreements 12
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 12
Equity Offering 14
Avanir Pharma Raises USD230 Million in Public Offering of Shares 14
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To US$150 Million 16
Avanir Pharma Increases Size Of Private Placement Of Shares For US$80 Million 17
Acquisition 18
Otsuka Acquires Avanir Pharma for USD3.5 Billion 18
Avanir Pharmaceuticals Inc – Key Competitors 20
Avanir Pharmaceuticals Inc – Key Employees 21
Avanir Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Product News 23
04/19/2017: Avanir Pharmaceuticals to Present Data on NUEDEXTA at American Academy of Neurology (AAN) 2017 Annual Meeting 23
Clinical Trials 24
Jun 07, 2017: Avanir Pharmaceuticals Initiates Phase II Study to Evaluate AVP-786 for Treatment of Neurobehavioral Disinhibition Associated with Traumatic Brain Injury 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Avanir Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 10
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 12
Avanir Pharma Raises USD230 Million in Public Offering of Shares 14
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To US$150 Million 16
Avanir Pharma Increases Size Of Private Placement Of Shares For US$80 Million 17
Otsuka Acquires Avanir Pharma for USD3.5 Billion 18
Avanir Pharmaceuticals Inc, Key Competitors 20
Avanir Pharmaceuticals Inc, Key Employees 21
Avanir Pharmaceuticals Inc, Subsidiaries 22

List of Figures
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Avanir Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Xellia Pharmaceuticals ApS:製薬・医療:M&Aディール及び事業提携情報
    Summary Xellia Pharmaceuticals ApS (Xellia), a subsidiary of Novo A/S is a healthcare products provider that offers fermented and semi-synthetic APIs and injectable finished dosage forms. The company offers strain and fermentation development with bacteria and fungi. It provides injectable products …
  • Xeikon N.V.:企業の戦略的SWOT分析
    Xeikon N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Life Time Inc:企業の戦略的SWOT分析
    Life Time Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Hellenic Telecommunications Organization S.A. (HTO):企業の財務・戦略的SWOT分析
    Hellenic Telecommunications Organization S.A. (HTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s ke …
  • China National Biotec Group-製薬・医療分野:企業M&A・提携分析
    Summary China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group Corp is a manufacturer and distributor of vaccines, therapeutic products and diagnostic reagents. The company develops biological products for disease prevention, therapeutic and diagnostic use. Its produ …
  • Zenkyoren:企業の戦略・SWOT・財務情報
    Zenkyoren - Strategy, SWOT and Corporate Finance Report Summary Zenkyoren - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • BreitBurn Energy Partners L.P. (BBEP)-石油・ガス分野:企業M&A・提携分析
    Summary BreitBurn Energy Partners L.P. (BreitBurn Energy) is an independent upstream oil and gas partnership company that acquires assets, and explores, develops and produces oil and gas properties in the US. The company’s asset portfolio consist of producing and non-producing oil, Natural Gas Liqui …
  • Dare Bioscience Inc (DARE):医療機器:M&Aディール及び事業提携情報
    Summary Dare Bioscience Inc (Dare Bioscience), formerly Cerulean Pharma Inc, is a clinical stage biopharmaceutical company that develops products for women’s reproductive health. The company, through its dynamic tumor targeting platform, creates nanoparticle drug conjugates to attack tumor cells, re …
  • Berkem SA:戦略・SWOT・企業財務分析
    Berkem SA - Strategy, SWOT and Corporate Finance Report Summary Berkem SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • GraceKennedy Ltd (GK):企業の財務・戦略的SWOT分析
    GraceKennedy Ltd (GK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Pyxant Labs Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pyxant Labs Inc (Pyxant) is a bioanalytical laboratory that offers laboratory services. The laboratory’s services include picogram-level bioanalytical method development and validation, analytical and bioanalytical support for ADME studies, and analytical and bioanalytical support for pharma …
  • Sir Robert McAlpine Ltd:企業の戦略的SWOT分析
    Sir Robert McAlpine Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • CooperVision Inc:医療機器:M&Aディール及び事業提携情報
    Summary CooperVision Inc (CooperVision), a subsidiary of The Cooper Companies Inc, designs and manufactures soft contact lenses. It manufactures a wide array of monthly, two-week and daily disposable contact lenses. CooperVision helps overcome various vision challenges such as astigmatism and presby …
  • Sempra Energy:企業の戦略・SWOT・財務情報
    Sempra Energy - Strategy, SWOT and Corporate Finance Report Summary Sempra Energy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • SES SA (SESG):企業の財務・戦略的SWOT分析
    SES SA (SESG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Neuralstem Inc:企業のM&A・事業提携・投資動向
    Neuralstem Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Neuralstem Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Kuwait Investment Authority:電力:M&Aディール及び事業提携情報
    Summary The Kuwait Investment Authority (KIA) is an asset management company. It offers fund management and investment management services. The company is responsible for the management and administration of the General Reserve Fund (GRF), apart from the assets of the Future Generations Fund (FGF). …
  • Ritter Pharmaceuticals Inc (RTTR):製薬・医療:M&Aディール及び事業提携情報
    Summary Ritter Pharmaceuticals Inc (Ritter) is a developer of therapeutic products for gastrointestinal diseases. The company’s lead product includes RP-G28, which is developed stimulate the growth of lactose-metabolizing bacteria in the colon to assist in digesting process. Its product is under the …
  • Fresenius Kabi USA LLC:企業の戦略的SWOT分析
    Fresenius Kabi USA LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Miromatrix Medical Inc:企業の製品パイプライン分析
    Summary Miromatrix Medical Inc (Miromatrix Medical) is a biotechnology company engaged in the development extracellular matrix based medical devices in soft tissue reinforcement and advanced wound care. The company offers MIRODERM a porcine liver-derived noncrosslinked acellular biologic wound matri …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆